醫藥組成物於製備不正常多麩醯胺聚集類疾病之藥物上之用途

專利類型

發明

專利國別 (專利申請國家)

中華民國

專利申請案號

102130549

專利證號

I 507202

專利獲證名稱

醫藥組成物於製備不正常多麩醯胺聚集類疾病之藥物上之用途

專利所屬機關 (申請機關)

國立臺灣師範大學

獲證日期

2015/11/11

技術說明

小腦萎縮症與致病基因中CAG 重復擴增轉譯出長的多麩醯胺鏈蛋白相關。錯誤摺疊的多麩醯胺蛋白堆積細胞核或質內會導致活性氧分子增加及細胞死亡。因此抑制蛋白聚集及降低活性氧壓力可能抑制衍生的下游有害事件，提供小腦萎縮症的可能治療策略。本研究發現山梔子及活性成份geniposide、crocin可藉增強抗氧化功能，來抑制擴增的多麩醯胺蛋白聚集。山梔子、geniposide及crocin在表現ATXN3/Q75-GFP且誘導神經分化的SH-SY5Y細胞中，亦可抑制多麩醯胺蛋白聚集。以上實驗結果顯示中藥山梔子及geniposide、crocin在臨床上有潛能被應用來治療小腦萎縮症。 In SCA, the expansions of translated CAG repeats in the disease genes result in long polyQ tracts in the respective proteins. The accumulation of intranuclear and cytoplasmic misfolded polyQ proteins is thought to induce oxidative stress and lead to cell death. Thus suppression of aggregation and reducing ROS are expected to inhibit a wide range of harmful downstream events, providing an observation for identifying the potential treatment of SCA. In this study, we tested the aqueous extract of G. jasminoides and its constituents. We found the aggregation can be significantly prohibited by G. jasminoides and its active compounds geniposide and crocin. Meanwhile, G. jasminoides, geniposide and crocin enhanced antioxidative activity in the same cell models. All of them further reduced the aggregation in neuronal differentiated SH-SY5Y ATXN3/Q75-GFP cells. Our results provide potential therapeutics for the protein deposition-mediated diseases.

備註

本部(發文號1100066083)同意貴校110年8月30日師大研合字第1101021150號函申請終止維護專利。(師大)

連絡單位 (專責單位/部門名稱)

產學合作組

連絡電話

77341329

網址